Incorporating AI to Make 3D Procedural Planning More User-Friendly

In addition, Materialise has expanded its partnership with Fluidda, a global leader in lung imaging technology, to combine Fluidda's AI technology with Materialise's 3D planning software expertise. Through a joint research and development initiative, Fluidda's AI technology will be integrated within Materialise's medical software to expedite and improve personalized 3D visualizations for respiratory diseases such as COPD, asthma, IPF and lung cancer. Through improved patient selection and preprocedural planning, the companies aim to make treatment outcomes more predictable and reduce the risk for intra-procedural complications.


"Our objective in this research and development project is to make 3D imaging and planning software more user friendly, efficient and automated," said Brigitte de Vet, Vice President, Medical at Materialise. "Dedicated 3D planning solutions will enable clinical care teams to make better-informed decisions for every patient suffering from lung disease."

As part of this expanded R&D partnership, Materialise will also combine its advanced 3D visualization and planning technology with Fluidda's portfolio of pulmonology services to support medical device companies in developing new respiratory treatments.



Bringing Treatment Expertise to Patients around the World

Materialise and Zealise Medical (振源), who support surgeons in their preparation for lung segmentectomies through 3D planning services and software, have founded the China-based joint venture Tianjin Zhenyuan Materialise Medical Technology to further develop the Mimics Enlight 3D Lung software. China is the country with the highest cancer-related death rate and a lung cancer rate of more than 35 cases per 100,000 residentsii. Last year, surgeons in China leveraged Zealise Medical (振源) and Materialise's solutions to prepare for more than 6,000 segmentectomy procedures. NMPA submission for Mimics Enlight 3D Lung software is currently pending in China.

While this approach to lung cancer treatment has seen considerable adoption in China, there is now an opportunity to bring the benefits of 3D planning and personalized care to more lung cancer patients around the world. According to Prof. Dr. Herbert Decaluwé, Thoracic Surgeon, U.Z. Leuven, Belgium: "As evidence continues to build, the number of minimally invasive lobectomies and segmentectomies, for which advanced 3D visualizations are very helpful, is expected to further increase in Europe in the coming years."

CT Homepage